Quarterly earnings increases through the Jun '17 quarter were above the +25% minimum earnings (C criteria) guideline. Since a downturn and loss in FY '13 the company's annual earnings (A criteria) increases have been strong. The company hails from the Medical - Products industry group which has a strong 96 Group Relative Strength Rating, a reassuring sign concerning the L criteria. The number of top-rated funds owning an interest rose from 184 in Sep '16 to 273 in Jun '17, a reassuring sign concerning the I criteria.